![[ICO]](/icons/blank.gif){kind=icon}
![[PARENTDIR]](/icons/back.gif){kind=icon}
![[ ]](/icons/unknown.gif){kind=icon}
![[ ]](/icons/layout.gif){kind=icon}
![[ ]](/icons/compressed.gif){kind=icon}
| Name | Last modified | Size | Description |
|---|---|---|---|---|
| Parent Directory | - | ||
| Intervalli_confidenz..> | 2006-10-24 09:49 | 232K | |
| allocation concealme..> | 2007-03-14 12:33 | 158K | |
| studio fase 1.pdf | 2008-09-23 07:58 | 526K | |
| studio fase 2.pdf | 2008-09-23 15:19 | 131K | |
| potenza_studio.ppt | 2008-09-24 08:06 | 163K | |
| Optimal2-StageDesign..> | 2008-09-24 08:10 | 587K | |
| fase2.ppt | 2008-09-24 08:18 | 391K | |
| studio fase 3.pdf | 2008-09-24 13:44 | 723K | |
| Analisi_ripetute.ppt | 2008-09-25 11:00 | 203K | |
| CRF TRIBE vers 1.0 0..> | 2008-09-29 17:26 | 170K | |
| Part 1.3 | 2008-09-29 17:26 | 141 | |
| clinical trial doman..> | 2008-11-25 16:15 | 31K | |
| clinical trial doman..> | 2009-01-20 13:52 | 29K | |
| ctc_ecog.pdf | 2010-09-14 07:45 | 29K | |
| Orlowski_bortezomid_..> | 2010-09-14 07:52 | 278K | |
| fase1.ppt | 2010-09-14 07:53 | 200K | |
| Esempio_faseIII_CE71..> | 2010-09-15 10:53 | 593K | |
| Phase 4 studies.ppt | 2010-09-15 10:59 | 316K | |
| fase3_riv.ppt | 2010-09-15 11:14 | 1.9M | |
| MA_X_Master.ppt | 2010-09-15 15:10 | 719K | |
| [Medicina (14), 2010..> | 2010-09-15 16:28 | 492K | |
| XLS5.zip | 2010-09-16 11:01 | 6.4M | |